https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.858137/full
Frontiers | Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment...
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are two highly prevalent human diseases caused by excessive fat deposition...